SOUL Trial: Oral Semaglutide and MACE Reduction Cardiovascular protection from an oral GLP-1 in high-risk type 2 diabetes. Diabzen, [S. l.], v. 4, n. 19, p. 38–39, 2026. Disponível em: https://thediabzen.com/index.php/d/article/view/62. Acesso em: 29 jul. 2026.